Intercollegiate Advisory Committee for Sedation in Dentistry

Remimazolam for intravenous conscious sedation for dental procedures

IACSD standard on clinical use and training

The Intercollegiate Advisory Committee for Sedation in Dentistry (IACSD) sets the current standards for clinical use and training for dentists and doctors providing sedation, in all environments, for dentistry in the UK. This is the overarching dental standards document for conscious sedation for dentistry from which devolved professional guidance may be predicated. The current standards document pre-dates Remimazolam authorisation. The advice below sets out the expected standard of clinical use and training to enable safe use of Remimazolam until an established evidence base becomes available. Those providing conscious sedation for dentistry will be expected to comply with this standard.

- Remimazolam, titrated intravenously as a single drug in adults, shall be used adhering to the same clinical standards and training required for midazolam.
- The technique is classified as an operator-sedationist technique.
- An appropriate adult escort is required for post-sedation care, in the same way as for the use of intravenous midazolam.
- Remimazolam and midazolam should not be used in combination or sequentially on a routine basis and without adequate justification for the same episode of sedation in primary care.
- Remimazolam should be reconstituted, drawn up and clearly labelled by the clinician administering the drug.
- Providers of intravenous conscious sedation for dentistry, trained and experienced in the use of midazolam to IACSD standards, do not require further supervised clinical experience. However, clinicians must consult the manufacturer's product literature and have knowledge of pharmacology, dosing and indications together with an understanding of how these fit with the IACSD standards. Evidence of this can be gained through CPD courses with appropriately set aims and objectives.

Please note that this information is for patients over eighteen years of age. Our advice is that this drug should not yet be used in younger patients until further evidence becomes available.

 IACSD Standards for Conscious Sedation in the Provision of Dental Care (V1.1) – 2020 Report

9 January 2023. To be reviewed in six months.

The Intercollegiate Advisory Committee for Sedation in Dentistry is an intercollegiate committee of the following:-